Gene signature helps identify risk of relapse in lung cancer patients

A new genetic signature identified by Spanish researchers may provide doctors with robust and objective information about which patients with early stage lung cancer are at low or high risk of relapse following surgery, investigators report at the 3rd European Lung Cancer Conference in Geneva. Their work also opens new avenues for immunotherapy for lung cancer.

Non-small cell lung cancer is a disease that is often not diagnosed until it has grown and spread throughout the body. Even those who are diagnosed early enough to undergo surgical removal of the tumor still have a discouraging 30% rate of relapse.

Researchers hope that identifying which patients have the greatest risk of relapse will allow doctors to focus other treatment strategies, in order to improve their chance of being cured after surgery.

A multidisciplinary team of researchers from Hospital Clinico San Carlos, Madrid, have found a 50-gene predictor that appears to be capable of doing just that. In a study of 84 patients with stage I and II non-small cell lung cancer, who had undergone surgery to remove their tumor, the gene signature accurately predicted which patients were at low risk of relapse.

The researchers analyzed in the tumor mass using microarray technology. Following patients for six years, they were able to correlate with the clinical course of disease, and the risk of relapse.

The Spanish research team's report at the meeting shows that the genes of the predictor were over-expressed in roughly one-third of patients, all of whom had a low risk of relapse. Further analysis showed that these genes were related to the activity of important immune system , known as B lymphocytes.

"All of these genes overexpressed in the low-risk group are highly related to activity," said Dr Florentino Hernando presenting the results at the meeting. "So, the B cell-mediated immune response seems to have a very important role."

The genetic profile identified by the researchers suggests that low-risk patients have an enhanced immune response against the tumor. "Thus, treatments that may interfere with this response such as post-surgical chemotherapy must be reconsidered for the low-risk subgroup," he says.

"One third of patients show an overexpression of an 'immune' in their tumor specimens, that is associated with better prognosis," Dr Hernando said. "The fact that this B cell-dependent was associated to the good outcome suggests we should investigate its therapeutic applications in the management of these patients after surgical resection."

Commenting on the study, which he was not involved in, Prof David Carbone from the Vanderbilt-Ingram Cancer Center, member of the IASLC Board, said: "The Spanish group studied tumors from 84 patients with completely resected stage I and II for gene RNA expression profiles using 41,000 different probes. Since over half of these patients relapse and die from their cancer in spite of complete resection, there is a pressing need for both defining those patients at the greatest risk of relapse for trials of adjuvant therapy, but also potentially avoiding the toxicity of adjuvant therapy in patients with a low risk of relapse. This is a potentially extremely important classifier, which if independently validated, could be the basis of such a test. It is interesting that the majority of the genes in the classifier are either immune-derived or immunomodulatory, suggesting a potential molecular basis for this observation. It would be interesting to compare the results of this classifier to simple quantitation of lymphocytic infiltration into the resected tumors.

Provided by European Society for Medical Oncology

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

New biomarker that predicts breast cancer relapse found

May 16, 2011

Researchers from Virginia Commonwealth University Massey Cancer Center have discovered a new biomarker related to the body's immune system that can predict a breast cancer patients' risk of cancer recurrence. This breakthrough ...

New genetic techniques to combat lung cancer

Apr 25, 2008

New results on genetic techniques that are helping doctors diagnose and treat lung cancer were released today at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) ...

Genetic pattern that predicts leukemia relapse discovered

May 11, 2010

A genetic pattern that predicts the likelihood of relapse in patients with one of the most aggressive forms of childhood leukemia has been discovered. Researchers publishing in the open access journal Molecular Cancer have i ...

Recommended for you

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.